Is Biodexa Pharmaceuticals PLC halal to invest in?

According to Musaffa's Shariah screening methodology, Biodexa Pharmaceuticals PLC (BDRX) is currently classified as NOT HALAL as of April 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Biodexa Pharmaceuticals PLC a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Biodexa Pharmaceuticals PLC using these criteria to determine its compliance status.

Can Muslims buy shares of Biodexa Pharmaceuticals PLC?

Muslim investors may consider investing in Biodexa Pharmaceuticals PLC if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Biodexa Pharmaceuticals PLC classified as NOT HALAL?

Musaffa determines the Shariah status of Biodexa Pharmaceuticals PLC by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Biodexa Pharmaceuticals PLC updated?

The Shariah compliance status of Biodexa Pharmaceuticals PLC may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Biodexa Pharmaceuticals PLC become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Biodexa Pharmaceuticals PLC?

You can check the latest Shariah compliance status of Biodexa Pharmaceuticals PLC on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

BDRX Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: April 30, 2026

Report Source: 2025 Annual Report

Biodexa Pharmaceuticals PLC. Stock Analysis BDRX

United States Health Care Nano Cap Report: 2025 Annual

Biodexa Pharmaceuticals Plc is a drug delivery technology company. The company is headquartered in Abingdon, Oxfordshire and currently employs 11 full-time employees. The company went IPO on 2014-12-08. The firm is developing a pipeline of products for the treatment of diseases with unmet medical needs. The Company’s lead development program, eRapa, is under development for familial adenomatous polyposis and non-muscle invasive bladder cancer; tolimidone, under development as a for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive rare/orphan brain cancer indications, including recurrent glioblastoma, diffuse midline glioma, or DMG, and medulloblastoma. Its technologies include Q-Sphera, MidaCore and MidaSolve. The Q-Sphera platform is a polymer microsphere microtechnology used for sustained delivery to prolong and control the release of therapeutics over an extended period of time, from weeks to months. Its MidaSolve platform is an oligosaccharide nanotechnology that is used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors.

Key Statistics of Biodexa Pharmaceuticals PLC (BDRX)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$3.05$3.33

Today's Open

$3.33

Volume

28.39K

P/E Ratio (TTM)

52 Week Range

$2.86$96.50

Market Cap

1.41M

Avg. Volume

863.44K

Dividend Yield

Financial Metrics & Statements of Biodexa Pharmaceuticals PLC (BDRX)

FAQ's for Biodexa Pharmaceuticals PLC (BDRX)

According to Musaffa’s Shariah screening methodology, Biodexa Pharmaceuticals PLC (BDRX) is currently classified as NOT HALAL as of April 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.